Latest articles

Research Director at INRA, Joël is Scientific Director of MetaGenoPolis (www.mgps.eu). He is the leader of the team ‘functionalities of the intestinal ecosystem’ within the Micalis Institute “Food and Gut Microbiology for Human Health” (http://www.micalis.fr/micalis_eng/Poles-and-teams/Pole-Ecosystems/FInE-Dore)…

Scientists and clinicians examine the latest research in the role human gut microbes play indigestive and overall health at the Gut Microbiota for Health Summit 2014 (March 8-9 - Miami, USA), hosted by the ESNM and the AGA.     Go to part 2. [View the story "#GMFH2014 on the Web [Part 1 of 3]" on Storify]

In this study, Aviles-Jimenez and co-workers aimed to characterize microbiota of the gastric mucosa as its progress to intestinal type of cancer. To do that, they analysed gastric tissue in patients with non-atrophic gastritis (NAG), intestinal metaplasia (IM) and intestinal-type gastric cancer (GC). After performing genetic analyses on the samples, the researchers quantified a low bacterial diversity in all samples, ranged form 8 (in GC patients) to 57 (in NAG), with IM as an intermediate group. Also, they found that Firmicutes and Proteobacteria represented almost the 70% of phyla in all samples. Interestingly, they observed a gradual decrease in gastric microbiota profile from NAG to IM to GC. In particular,…

It is known that disruption of gut microbiota by use of antibiotics makes individuals more vulnerable to Clostridium difficile infection (CDI). Also, antibiotic treatment for CDI can eliminate potentially protective commensal bacteria, which could, in turn, facilitate Clostridium difficile reinfection. Thus, recurrence of those infections remains a clinical challenge.   In this “Between Bedside to Bench” article in the Nature Medicine journal, Taur and Pamer discussed the potential of fecal microbiota transplant (FMT) to treat or even prevent Clostridium difficile infection, as an alternative approach to reconstruct microbiota in patients with recurrent CDI. Moreover, the authors examined several studies that proposed different mechanisms to explain FMT efficacy. As the authors…

Twitter

Twitter


Follow @GMFHx
Upcoming events
See all events
News archive
Access from here to the chronological archive of news of this site
Access archive
Research & Practice
Latest articles

Research Director at INRA, Joël is Scientific Director of MetaGenoPolis (www.mgps.eu). He is the leader of the team ‘functionalities of the intestinal ecosystem’ within the Micalis Institute “Food and Gut Microbiology for Human Health” (http://www.micalis.fr/micalis_eng/Poles-and-teams/Pole-Ecosystems/FInE-Dore)…

Scientists and clinicians examine the latest research in the role human gut microbes play indigestive and overall health at the Gut Microbiota for Health Summit 2014 (March 8-9 - Miami, USA), hosted by the ESNM and the AGA.     Go to part 2. [View the story "#GMFH2014 on the Web [Part 1 of 3]" on Storify]

In this study, Aviles-Jimenez and co-workers aimed to characterize microbiota of the gastric mucosa as its progress to intestinal type of cancer. To do that, they analysed gastric tissue in patients with non-atrophic gastritis (NAG), intestinal metaplasia (IM) and intestinal-type gastric cancer (GC). After performing genetic analyses on the samples, the researchers quantified a low bacterial diversity in all samples, ranged form 8 (in GC patients) to 57 (in NAG), with IM as an intermediate group. Also, they found that Firmicutes and Proteobacteria represented almost the 70% of phyla in all samples. Interestingly, they observed a gradual decrease in gastric microbiota profile from NAG to IM to GC. In particular,…

It is known that disruption of gut microbiota by use of antibiotics makes individuals more vulnerable to Clostridium difficile infection (CDI). Also, antibiotic treatment for CDI can eliminate potentially protective commensal bacteria, which could, in turn, facilitate Clostridium difficile reinfection. Thus, recurrence of those infections remains a clinical challenge.   In this “Between Bedside to Bench” article in the Nature Medicine journal, Taur and Pamer discussed the potential of fecal microbiota transplant (FMT) to treat or even prevent Clostridium difficile infection, as an alternative approach to reconstruct microbiota in patients with recurrent CDI. Moreover, the authors examined several studies that proposed different mechanisms to explain FMT efficacy. As the authors…

Meet our board of experts